Johan M. Spoor Acquires 14,500 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor acquired 14,500 shares of Perspective Therapeutics stock in a transaction on Monday, November 25th. The stock was purchased at an average cost of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $4.12 on Thursday. The company’s 50 day simple moving average is $10.96. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. As a group, research analysts forecast that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CATX shares. UBS Group started coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Oppenheimer dropped their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Wedbush reiterated an “outperform” rating and issued a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Finally, Truist Financial began coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.14.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently modified their holdings of the business. Barclays PLC lifted its stake in shares of Perspective Therapeutics by 587.9% during the 3rd quarter. Barclays PLC now owns 114,075 shares of the company’s stock valued at $1,523,000 after buying an additional 97,493 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Perspective Therapeutics by 12.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after buying an additional 129,654 shares in the last quarter. XTX Topco Ltd bought a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $498,000. State Street Corp increased its holdings in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.